2 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 4 Phase 1, 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Protein Kinase Inhibitors: new trials by email Literature Review of Protein Kinase Inhibitors trials Research Report on Protein Kinase Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT) - Coronary Disease, Heart Diseases | Not applicable | Recruiting | Fondazione Ricerca e Innovazione Cardiovascolare ETS | 576 | 2026-01-10 | 2026-01-22 |
| Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors JYP0322 50 mg qd, JYP0322 100 mg qd, JYP0322 200 mg qd - Protein Kinase Inhibitors, Other Protocol Specified Criteria | Phase 1 | Recruiting | Guangzhou JOYO Pharma Co., Ltd | 101 | 2022-05-04 | 2025-07-14 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
| TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC TACE combined with sorafenib and PD-1 mAb - Hepatocellular Carcinoma, Liver Neoplasms | Phase 2 | Completed | Sichuan Cancer Hospital and Research Institute | 27 | 2020-09-14 | 2024-06-25 |
| Savolitinib vs. Sunitinib in MET-driven PRCC. Savolitinib, Sunitinib - Carcinoma, Carcinoma, Renal Cell | Phase 3 | Active not recruiting | AstraZeneca | 60 | 2017-07-25 | 2026-07-14 |
| A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. JNJ-26483327 - Protein Kinase Inhibitors, Antineoplastic Protocols | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 19 | 2006-08-01 | 2010-04-26 |
Carcinoma (3) · Lung Neoplasms (3) · Neoplasms by Site (3) · Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Nerve Tissue (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Acute Coronary Syndrome (1)
Neoplasms, Glandular and Epithelial (4) · Neoplasms (3) · Adenocarcinoma (2) · Bronchial Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Arteriosclerosis (1) · Brain Diseases (1) · Carcinoma (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Digestive System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Lung Diseases (1)
osimertinib (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · BID protein, human (1) · Carboplatin (1) · JNJ-26483327 (1) · Pemetrexed (1) · Sorafenib (1) · Sunitinib (1)
Blueprint Medicines Corporation (2) · AstraZeneca (1) · Fondazione Ricerca e Innovazione Cardiovascolare ETS (1) · Guangzhou JOYO Pharma Co., Ltd (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Sichuan Cancer Hospital and Research Institute (1)
United States (3) · China (2) · France (2) · Italy (2) · South Korea (2) · Brazil (1) · Canada (1) · Japan (1) · Netherlands (1) · Russia (1) · Singapore (1) · Spain (1) · Taiwan (1) · Ukraine (1) · United Kingdom (1)
Li Zhang, M.D. (1) · Toni K Choueiri, MD (1)
2016 (1)